Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose?

Future Medicinal Chemistry

Volumn 4, Issue 2, 2012, Pages 125-128

  Zheng, Fang ^a   Zhan, Chang Guo ^a  

^a University of Kentucky   (United States)

Author keywords

drug abuse; drug addiction; drug metabolism; drug overdose; pharmacokinetic agent; therapeutic enzyme

Indexed keywords

DOPAMINE TRANSPORTER; DRUG METABOLIZING ENZYME;

COCAINE DEPENDENCE; DRUG OVERDOSE; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THORAX PAIN;

COCAINE; COCAINE-RELATED DISORDERS; FEASIBILITY STUDIES; HUMANS; OVERDOSE; PHARMACOKINETICS;

EID: 84856943641     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.171     Document Type: Review

References (16)

1. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs 64, 1547-1573 (2004). (Pubitemid 38981839)
2. Pan Y, Gao D, Yang W et al. Computational redesign of human butyrylcholinesterase for anti-cocaine medication. Proc. Natl Acad. Sci. USA 102, 16656-16661 (2005). (Pubitemid 41688832)
3. Zheng F, Yang W, Ko MC et al. Most efficient cocaine hydrolase designed by virtual screening of transition States. J. Am. Chem. Soc. 130, 12148-12155 (2008).
4. Xue L, Ko MC, Tong M et al. Rational design, preparation and characterization of high-activity mutants of human butyrylcholinesterase against (-)-cocaine. Mol. Pharmacol. 79, 290-297 (2011).
5. Gao D, Narashihan DL, Macdonald J et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol. Pharmacol. 75, 318-323 (2009).
6. Huang X, Gu H, Zhan CG. Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J. Phys. Chem. B 113, 15057-15066 (2009).
7. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann. NY Acad. Sci. 1187, 316-340 (2010).
8. Landry DW, Zhao K, Yang GXQ, Glickman M, Georgiadis TM. Antibody catalyzed degradation of cocaine. Science 259, 1899-1901 (1993).
9. Moreno AY, Janda HD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmaco. Biochem. Behavior. 92, 199-205 (2009).
10. Kinsey BM, Kosten TR, Orson FM. Anti-cocaine vaccine development. Expert Rev. Vaccines 9, 1109-1114 (2010).
11. Norman AB, Norman MK, Buesing WR, Tabet MR, Tsibulsky VL, Ball WJ. The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 328, 873-881 (2009).
12. Collins GT, Carey KA, Narasimhan D et al. Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology 36, 1047-1059 (2011).
13. Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum - a hydrolase gene therapy approach. J. Pharmacol. Exp. Ther. 330, 449-457 (2009).
14. Barnett G, Hawks R, Resnick R. Cocaine pharmacokinetics in humans. J. Ethnopharmacol. 3, 353-366 (1981).
15. Fowler JS, Kroll C, Ferrieri R et al. PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine. J. Nucl. Med. 48, 1724-1732 (2007). (Pubitemid 47577345)
16. Brimijoin S, Gao Y, Anker JJ et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33, 2715-2725 (2008).